vancomycin has been researched along with op-1118 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babakhani, F; Gomez, A; Robert, N; Sears, P | 1 |
| Crook, DW; Louie, TJ; Miller, MA; Sears, P; Weiss, K | 1 |
| Babakhani, F; Citron, DM; Goldstein, EJ | 1 |
| Babakhani, F; Bouillaut, L; Gomez, A; Nguyen, L; Sears, P; Sonenshein, AL | 1 |
| Allen, CA; Babakhani, F; Nguyen, L; Sears, P; Sorg, JA | 1 |
| Babakhani, F; Bouillaut, L; Gomez, A; Sears, P; Sims, C; Sonenshein, AL | 1 |
| Chen, X; Cheng, M; Hing, TC; Ho, S; Ichikawa, Y; Kelly, CP; Koon, HW; Pothoulakis, C | 1 |
1 trial(s) available for vancomycin and op-1118
| Article | Year |
|---|---|
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
Topics: Administration, Oral; Aged; Aminoglycosides; Anti-Bacterial Agents; Chromatography, Liquid; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Feces; Female; Fidaxomicin; Humans; Male; Middle Aged; Severity of Illness Index; Tandem Mass Spectrometry; Treatment Outcome; Vancomycin | 2012 |
6 other study(ies) available for vancomycin and op-1118
| Article | Year |
|---|---|
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Fidaxomicin; Microbial Sensitivity Tests; Time Factors; Vancomycin | 2011 |
Antimicrobial activities of fidaxomicin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials as Topic; Clostridioides difficile; Clostridium Infections; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Feces; Fidaxomicin; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Recurrence; Vancomycin | 2012 |
Fidaxomicin inhibits spore production in Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Load; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Gene Expression Regulation, Bacterial; Genes, Bacterial; Metronidazole; Microbial Sensitivity Tests; Rifamycins; Rifaximin; Spores, Bacterial; Vancomycin | 2012 |
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Culture Media; Fidaxomicin; Microbial Sensitivity Tests; Spores, Bacterial; Taurocholic Acid; Vancomycin | 2013 |
Fidaxomicin inhibits toxin production in Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Culture Media; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Fidaxomicin; Gene Expression; Gene Expression Profiling; Humans; Metronidazole; Vancomycin | 2013 |
Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Toxins; Clostridioides difficile; Edema; Enterocolitis, Pseudomembranous; Enterotoxins; Epithelial Cells; Fibroblasts; Fidaxomicin; Gene Expression; Ileum; Injections, Intralesional; Interleukin-1beta; Intestinal Mucosa; Male; Metronidazole; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; RNA, Messenger; Vancomycin | 2014 |